Last reviewed · How we verify
Azithropycin according to symptoms
Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Bacterial infections including respiratory tract infections, otitis media, and skin infections, Atypical infections caused by Mycoplasma, Chlamydia, and Legionella species, Prophylaxis of Mycobacterium avium complex in immunocompromised patients.
At a glance
| Generic name | Azithropycin according to symptoms |
|---|---|
| Sponsor | University Hospital, Montpellier |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit (23S rRNA) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Azithromycin binds to the bacterial 23S rRNA component of the 50S ribosomal subunit, preventing peptide bond formation and elongation of the bacterial polypeptide chain. This results in bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria, as well as some atypical organisms. The drug accumulates in tissues and has a long half-life, allowing for extended dosing intervals.
Approved indications
- Bacterial infections including respiratory tract infections, otitis media, and skin infections
- Atypical infections caused by Mycoplasma, Chlamydia, and Legionella species
- Prophylaxis of Mycobacterium avium complex in immunocompromised patients
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
- Headache
- Vaginitis
- QT prolongation
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: